Texas Permanent School Fund lessened its holdings in shares of Mylan NV (NASDAQ:MYL) by 3.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,312 shares of the company’s stock after selling 3,401 shares during the period. Texas Permanent School Fund’s holdings in Mylan were worth $2,843,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of Mylan by 2.6% during the 4th quarter. BlackRock Inc. now owns 39,965,771 shares of the company’s stock valued at $1,095,061,000 after purchasing an additional 1,018,811 shares in the last quarter. Vanguard Group Inc lifted its holdings in shares of Mylan by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 35,774,112 shares of the company’s stock valued at $1,309,333,000 after purchasing an additional 506,649 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Mylan by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after purchasing an additional 1,026,731 shares in the last quarter. Norges Bank bought a new position in shares of Mylan during the 4th quarter valued at about $169,463,000. Finally, Oregon Public Employees Retirement Fund lifted its holdings in shares of Mylan by 2,715.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,145,628 shares of the company’s stock valued at $224,000 after purchasing an additional 5,927,314 shares in the last quarter. Institutional investors and hedge funds own 83.69% of the company’s stock.
Several equities research analysts have commented on the company. Morgan Stanley set a $32.00 target price on Mylan and gave the company a “buy” rating in a research note on Wednesday, May 8th. BidaskClub upgraded Mylan from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 30th. Royal Bank of Canada cut their target price on Mylan to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 8th. Mizuho restated a “neutral” rating on shares of Mylan in a research note on Thursday, January 31st. Finally, Credit Suisse Group restated a “buy” rating and issued a $37.00 target price on shares of Mylan in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $37.35.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.03. The business had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.96 EPS. Equities analysts anticipate that Mylan NV will post 4.28 earnings per share for the current fiscal year.
In other news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $27.50, for a total transaction of $317,157.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.81% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: Straddles
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.